Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AstraZeneca's PD-L1 Works, But Probably Not Enough For Lung Cancer Filing

This article was originally published in Scrip

Executive Summary

AstraZeneca PLC's chief medical officer has warned once again that a trial of the company's PD-L1 inhibitor durvalumab will not provide strong enough data to support a regulatory submission for the drug as a standalone treatment for advanced lung cancer. However, preliminary findings from the company's lead monotherapy trial, ATLANTIC, show that it does work.